CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
J. Li, T. Huang, J. Hua…·J. He
This paper develops and tests a CD46-targeted alpha radioimmunotherapy, 212Pb-TCMC-YS5, showing potent tumor growth inhibition and survival improvement in multiple prostate cancer models.